BCL2L11 and plasma cell myeloma: However, in contrast to Morelli et al. (2018) who recently successfully applied this approach in multiple myeloma, none of the GapmeRs tested was able to modulate BIM expression or promote the sensitivity of LUAD to cisplatin [31].